Slow Capital Inc. Has $3.22 Million Stake in Danaher Co. (NYSE:DHR)

Slow Capital Inc. lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,027 shares of the conglomerate’s stock after selling 524 shares during the period. Slow Capital Inc.’s holdings in Danaher were worth $3,223,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. Baldwin Wealth Partners LLC MA lifted its holdings in shares of Danaher by 6.2% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 80,108 shares of the conglomerate’s stock worth $18,389,000 after acquiring an additional 4,673 shares during the period. Foundations Investment Advisors LLC boosted its holdings in Danaher by 41.8% during the fourth quarter. Foundations Investment Advisors LLC now owns 2,321 shares of the conglomerate’s stock valued at $533,000 after purchasing an additional 684 shares in the last quarter. Parsons Capital Management Inc. RI grew its position in Danaher by 38.3% in the fourth quarter. Parsons Capital Management Inc. RI now owns 62,807 shares of the conglomerate’s stock valued at $14,417,000 after acquiring an additional 17,409 shares during the period. James Hambro & Partners LLP increased its position in shares of Danaher by 9.8% during the 4th quarter. James Hambro & Partners LLP now owns 309,594 shares of the conglomerate’s stock worth $71,087,000 after purchasing an additional 27,697 shares in the last quarter. Finally, Cornerstone Wealth Group LLC boosted its holdings in shares of Danaher by 9.1% in the 4th quarter. Cornerstone Wealth Group LLC now owns 1,179 shares of the conglomerate’s stock worth $271,000 after acquiring an additional 98 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $250.51 on Tuesday. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The company has a market cap of $180.94 billion, a PE ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The business’s 50 day moving average price is $235.33 and its two-hundred day moving average price is $253.62. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is 20.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on DHR shares. Scotiabank started coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. TD Cowen upped their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. KeyCorp upped their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus boosted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.